CEO of TechBio Platform Company Recruited by Occam Global
In October 2024, Occam recruited Thomas McCauley, PhD, as President and CEO of Neptune Bio, a NYC-based TechBio platform company backed by Lux Capital and KdT Ventures.
Tom joins Neptune from Omega Therapeutics, a Flagship incubated epigenetics platform company, where he has served as Chief Scientific Officer (CSO) from the company's infancy through crossover and a public offering.
Previously, Tom served as CSO of Macrolide Pharma and Translate Bio (acquired by Sanofi for $3.2B). He began his industrial career at Shire.
Tom received a BS and MEng in Applied and Engineering Physics from Cornell and his PhD in Condensed Matter and Materials Physics from the University of Alabama.
About Neptune Bio
Neptune Bio is dedicated to discovering combinatorial cures by identifying the distinct conditions that trigger cellular changes. Their platform integrates groundbreaking biological data with advanced artificial intelligence (AI) to model complex gene synergies, paving the way for the development of new combinatorial therapies.
Related Placements
Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.